Ligand Pharma (LGND) Income Statement

Click line-items for a historical chart and %

Revenues:
Royalties	15.7M
Material sales	4.22M
Collaborative research and development and other revenues	1.7M
Total revenues	21.62M
Operating costs and expenses:
Cost of sales	999K
Research and development	5.9M
General and administrative	6.31M
Lease exit and termination costs
Total operating costs and expenses	16.15M
Accretion of deferred gain on sale leaseback
Loss from operations	5.47M
Other income (expense):
Interest income
Interest expense	-3.12M
Decrease (increase) in liability for contingent value rights	-958K
Other, net	1.22M
Total other income (expense), net	-4.26M
Income (loss) before income taxes	1.21M
Income tax expense (benefit)	-160K
Income (loss) from continuing operations
Discontinued operations:
Discontinued operations	0
Net income (loss):	1.05M
Basic and diluted per share amounts:
Income (loss) from continuing operations
Discontinued operations
Net income (loss)
Weighted average number of common shares - basic	20.89M
Weighted average number of common shares - diluted	23M
AVINZA Product Line [Member]
Discontinued operations:
Gain on sale of a product line	0
Onocology Product Line [Member]
Discontinued operations:
Gain on sale of a product line

Entities mentioned with LGND